← FDA DRUG APPROVALS

FDA ANDA · ANDA212903

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE

Sponsor: ANNORA PHARMA

APPLICATION
ANDA212903
TYPE
ANDA
ORIGINAL APPROVAL
2024-10-18
LATEST ACTION
2024-10-18
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATEPrescription
MAGNESIUM SULFATE 1.6GM/BOT, POTASSIUM SULFATE 3.13GM/BOT, SODIUM SULFATE 17.5GM/BOT · SOLUTION · ORAL

Approval history

2024-10-18UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →